Changes in NKT cells. The presence of NKT cells was monitored by flow cytometry. PBMCs obtained from patients before starting therapy (PreC1), days 7 and 14 of cycle 1, before starting cycle 2 (PreC2), and at the completion of therapy (Post) were analyzed for the presence of iNKT cells using flow cytometry. The cells were stained with anti-CD3, Vα24, and Vβ11 antibodies. PBMCs were also analyzed using CD1d dimer either unloaded (Dimer control) or loaded with α-Galcer (Dimer Galcer). (A) Data from a representative patient during first cycle of therapy. (B) Summary of pooled data. Only patients with frequency of NKT cells above 0.01% at baseline were used to reliably estimate posttreatment decline in NKT cells. *P < .05; **P < .01.